Significant tumour shrinkage after 12 months of lanreotide Autogel‐120 mg treatment given first‐line in acromegaly
- 6 July 2009
- journal article
- clinical trial
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (2) , 237-245
Abstract
Summary: Objective To evaluate GH and IGF‐I control and tumour shrinkage in newly diagnosed patients with acromegaly treated first‐line with lanreotide‐Autogel (ATG) 120 mg.Design Open, prospective.Patients Twenty‐six patients (17 women, aged 31–70 years): eight enclosed and 12 extrasellar (eight invasive) macroadenomas and six microadenomas (one invasive). ATG 120 mg initially given every 4 weeks for 12 weeks; then intervals between injections increased to every 6 or 8 weeks if GH levels were ≤ 2·5 or < 1 µg/l (equal to 6·5 and 2·6 mU/l), respectively.Results Final dosage was ATG 120 mg every 4 weeks in nine patients (34·6%), every 6 weeks in eight patients (30·8%) and every 8 weeks in the remaining nine patients (34·6%). After 12 months, both GH and IGF‐I were controlled in 14 patients (53·8%). The mean tumour volume decreased from 1405 ± 1827 mm3 at study entry to 960 ± 1381 mm3 after 6 months, and 799 ± 1161 mm3 after 12 months (P < 0·0001). Overall tumour shrinkage was 35·8 ± 28·1% after 6 months and 48·4 ± 27·6% after 12 months. After 12 months, 20 patients (76·9%) achieved > 25% tumour shrinkage: 12 of 14 with controlled disease (85·7%) and 8 of 12 with noncontrolled disease (66·7%; P = 0·49). Hyperhydrosis, paresthesiae and arthralgias significantly reduced after treatment. No patient withdrew from the study because of adverse events.Conclusion ATG 120 mg in newly diagnosed patients with acromegaly controls GH and IGF‐I secretion in 53·8% and induces ≥ 25% tumour shrinkage in 76·9% during a 12‐month period. The treatment was associated with improvement of clinical symptoms and with a good safety profile.Keywords
This publication has 30 references indexed in Scilit:
- Control of IGF‐I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegalyClinical Endocrinology, 2008
- Lanreotide Autogel??Drugs, 2008
- A 12‐month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long‐acting repeatable on GH and IGF‐l in patients with acromegalyClinical Endocrinology, 2007
- Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effectiveClinical Endocrinology, 2007
- Efficacy of a slow‐release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal studyClinical Endocrinology, 2007
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trialClinical Endocrinology, 2006
- First‐line octreotide‐LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trialClinical Endocrinology, 2006
- Effectiveness and tolerability of 3-year lanreotide AutogelR treatment in patients with acromegalyClinical Endocrinology, 2006
- Treatment of acromegaly with octreotide‐LAR: extensive experience in a Brazilian institutionClinical Endocrinology, 2005